Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 8/20 | 0.44 |
| ▸ | MERTK | Q12866 | 2/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2207573 | 0.91 | NPY5R (0.49) | NPY5RMERTKSLC2A1AURKASRC | |
| SCHEMBL31471806 | 0.91 | NPY5R (0.49) | NPY5RMERTKSLC2A1AURKASRC | |
| SCHEMBL2200917 | 0.85 | NPY5R (0.47) | NPY5RMERTKSLC2A1AURKASRC | |
| SCHEMBL2205622 | 0.81 | MERTK (0.43) | NPY5RMERTKSLC2A1AURKASRC | |
| SCHEMBL2204708 | 0.77 | MERTK (0.60) | NPY5RMERTKSLC2A1AURKASRC | |
| SCHEMBL31471848 | 0.77 | NPY5R (0.49) | NPY5RMERTKSLC2A1AURKASRC | |
| SCHEMBL31471989 | 0.77 | NPY5R (0.52) | NPY5RMERTKSLC2A1AURKASRC | |
| SCHEMBL2207564 | 0.77 | AURKA (0.51) | NPY5RSLC2A1AURKASRCGSK3B | |
| SCHEMBL31471841 | 0.77 | AURKA (0.51) | NPY5RMERTKSLC2A1AURKASRC | |
| SCHEMBL12430664 | 0.77 | AURKA (0.74) | AURKASRCGSK3BNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989385-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-24 | — | — | US | disclosed |
| US-20030055068-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055068-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | NPY5R 1431/4885MERTK 1779/4885SLC2A1 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.